Annals of Oncology 7:827-835, 1996
© 1996 European Society for Medical Oncology
research-article |
Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-
Melanoma Section, Department of Melanoma/Sarcoma Medical Oncology, The University of Texas M.D. Anderson Cancer Center Houston, TX, USA
Correspondence to: Sewa S. Legha, MD Section of Melanoma Medical Oncology M.D. Anderson Cancer Center 1515 Holcombe Boulevard, Box 77 Houston, TX 77030, USA
BACKGROUND:: Metastatic melanoma is commonly treated with chemotherapy and/or biological agents used separately. In this study we have investigated the efficacy of combined chemotherapy using cisplatin, vinblastine, DTIC (CVD) and biological therapy using interleukin-2 (IL-2) and interferon-
(IFN-) in patients with metastatic melanoma.
PATIENTS AND METHODS:: All patients had advanced, inoperable melanoma without prior treatment with chemotherapy or biotherapy, a performance status of ECOG 0–2 and no evidence of symptomatic brain metastases. The CVD regimen consisted of cisplatin 20 mg/m2/d x 4, vinblastine 1.6 mg/m2/d x 5 and DTIC 800 mg/m2 x 1, repeated at 21-day intervals. The biotherapy regimen included IL-2, 9 x 106 IU/m2/d x 4 days and IFN- 5 x 106 U/m2/d SC x 5 days. The CVD and biotherapy regimens were integrated initially, in an alternating manner at 6-week intervals and subsequently, in a sequential fashion where patients were randomized to receive either CVD immediately followed by biotherapy (CVD/Bio) or the reverse sequence (Bio/CVD). Patients were admitted to the hospital for L-2 administration and for monitoring and treatment of IL-2 induced side effects. The phase II results of the integrated therapy (biochemotherapy) studies were retrospectively compared to our previously reported results with the CVD regimen used alone.
RESULTS:: The alternating biochemotherapy program was used in 40 patients and the sequential biochemotherapy was used in 62 patients. The alternating regimen produced 2 CRs and 11 PRs for an overall response rate of 33% among 39 evaluable patients. The sequential biochemotherapy produced 14 CRs and 23 PRs for an overall response rate of 60% (95% CI, 47% to 72%). The sequence of CVD/Bio resulted in a higher response rate (11 CRs + 11 PRs (69%)) compared to the Bio/CVD sequence (3 CRs + 12 PRs (50%)). Although the duration of PRs was short (median, 8 months), the median duration of CRs was 3+ years and 10 of 16 CRs are currently disease free for periods of 3+ to 6+ years. The median survival of patients receiving sequential biochemotherapy was 13 months compared to 9 months for the CVD treated group (P$$$ 0.04). Treatment with biochemotherapy was associated with severe toxicity including intense myelosuppression, infections, IL-2 induced constitutional toxicity and hypotension. However, the IL-2 induced toxicities were generally manageable on a regular ward, except for 15% of the patients who required transfer to an intensive care unit for treatment of complications associated with the treatment.
CONCLUSIONS:: The sequential combination of CVD with L-2 + IFN-a appears to have produced an increase in the number of durable responses in patients with metastatic melanoma. The toxicity of this program, although severe, was manageable. The biochemotherapy regimen produced an apparent increase in the median survival compared to that observed with the CVD regimen. However, a prospective comparison of these two regimens will be required to confirm these observations.
biochemotherapy, biotherapy, chemotherapy, interferon-, interleukin-2, melanoma
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. N. Markovic, L. A. Erickson, R. D. Rao, R. H. Weenig, B. A. Pockaj, A. Bardia, C. M. Vachon, S. E. Schild, R. R. McWilliams, J. L. Hand, et al. Malignant Melanoma in the 21st Century, Part 2: Staging, Prognosis, and Treatment Mayo Clin. Proc., April 1, 2007; 82(4): 490 - 513. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Hofmann, W. Sterry, and U. Trefzer Complex Combination Biochemotherapy Regimen in Advanced Metastatic Melanoma in a Non-intensive Care Unit: Toxicity or Benefit? Jpn. J. Clin. Oncol., March 1, 2007; 37(3): 224 - 229. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Kirkwood, S. Moschos, and W. Wang Strategies for the development of more effective adjuvant therapy of melanoma: current and future explorations of antibodies, cytokines, vaccines, and combinations. Clin. Cancer Res., April 1, 2006; 12(7): 2331s - 2336s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. F. Tse, M. Jeffers, V. A. Pollack, D. A. McCabe, M. L. Shadish, N. V. Khramtsov, C. S. Hackett, S. G. Shenoy, B. Kuang, F. L. Boldog, et al. CR011, a Fully Human Monoclonal Antibody-Auristatin E Conjugate, for the Treatment of Melanoma Clin. Cancer Res., February 15, 2006; 12(4): 1373 - 1382. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Keilholz, C. J.A. Punt, M. Gore, W. Kruit, P. Patel, D. Lienard, J. Thomas, T. M. Proebstle, A. Schmittel, D. Schadendorf, et al. Dacarbazine, Cisplatin, and Interferon-Alfa-2b With or Without Interleukin-2 in Metastatic Melanoma: A Randomized Phase III Trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group J. Clin. Oncol., September 20, 2005; 23(27): 6747 - 6755. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Hauschild, M. Weichenthal, B.-R. Balda, J. C. Becker, H. H. Wolff, W. Tilgen, K.-W. Schulte, J. Ring, D. Schadendorf, S. Lischner, et al. Prospective Randomized Trial of Interferon Alfa-2b and Interleukin-2 as Adjuvant Treatment for Resected Intermediate- and High-Risk Primary Melanoma Without Clinically Detectable Node Metastasis J. Clin. Oncol., August 1, 2003; 21(15): 2883 - 2888. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. O'Day, P. D. Boasberg, L. Piro, T. S. Kristedja, H.-J. Wang, M. Martin, R. Deck, P. Ames, K. Shinn, H. Kim, et al. Maintenance Biotherapy for Metastatic Melanoma with Interleukin-2 and Granulocyte Macrophage-Colony Stimulating Factor Improves Survival for Patients Responding to Induction Concurrent Biochemotherapy Clin. Cancer Res., September 1, 2002; 8(9): 2775 - 2781. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Islam, R. F. Frye, T. J. Richards, I. Sbeitan, S. S. Donnelly, P. Glue, S. S. Agarwala, and J. M. Kirkwood Differential Effect of IFN{alpha}-2b on the Cytochrome P450 Enzyme System: A Potential Basis of IFN Toxicity and Its Modulation by Other Drugs Clin. Cancer Res., August 1, 2002; 8(8): 2480 - 2487. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Eton, S. S. Legha, A. Y. Bedikian, J. J. Lee, A. C. Buzaid, C. Hodges, S. E. Ring, N. E. Papadopoulos, C. Plager, M. J. East, et al. Sequential Biochemotherapy Versus Chemotherapy for Metastatic Melanoma: Results From a Phase III Randomized Trial J. Clin. Oncol., April 15, 2002; 20(8): 2045 - 2052. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Bafaloukos, H. Gogas, V. Georgoulias, E. Briassoulis, G. Fountzilas, E. Samantas, Ch. Kalofonos, D. Skarlos, A. Karabelis, and P. Kosmidis Temozolomide in Combination With Docetaxel in Patients With Advanced Melanoma: A Phase II Study of the Hellenic Cooperative Oncology Group J. Clin. Oncol., January 15, 2002; 20(2): 420 - 425. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Buzaid and M. Atkins Practical Guidelines for the Management of Biochemotherapy-related Toxicity in Melanoma Clin. Cancer Res., September 1, 2001; 7(9): 2611 - 2619. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Jonasch and F. G. Haluska Interferon in Oncological Practice: Review of Interferon Biology, Clinical Applications, and Toxicities Oncologist, February 1, 2001; 6(1): 34 - 55. [Abstract] [Full Text]
|
|
|
|
|
|
E. A. Grimm, C. M. Smid, J. J. Lee, C.-H. Tseng, O. Eton, and A. C. Buzaid Unexpected Cytokines in Serum of Malignant Melanoma Patients during Sequential Biochemotherapy Clin. Cancer Res., October 1, 2000; 6(10): 3895 - 3903. [Abstract] [Full Text]
|
|
|
|
|
|
S. S. Agarwala and J. M. Kirkwood Temozolomide, a Novel Alkylating Agent with Activity in the Central Nervous System, May Improve the Treatment of Advanced Metastatic Melanoma Oncologist, April 1, 2000; 5(2): 144 - 151. [Abstract] [Full Text]
|
|
|
|
|
|
P. B. Chapman, L. H. Einhorn, M. L. Meyers, S. Saxman, A. N. Destro, K. S. Panageas, C. B. Begg, S. S. Agarwala, L. M. Schuchter, M. S. Ernstoff, et al. Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic Melanoma J. Clin. Oncol., September 1, 1999; 17(9): 2745 - 2745. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. O'Day, G. Gammon, P. D. Boasberg, M. A. Martin, T. S. Kristedja, M. Guo, S. Stern, S. Edwards, P. Fournier, M. Weisberg, et al. Advantages of Concurrent Biochemotherapy Modified by Decrescendo Interleukin-2, Granulocyte Colony-Stimulating Factor, and Tamoxifen for Patients With Metastatic Melanoma J. Clin. Oncol., September 1, 1999; 17(9): 2752 - 2752. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Richards, D. Gale, N. Mehta, and T. Lestingi Combination of Chemotherapy With Interleukin-2 and Interferon Alfa for the Treatment of Metastatic Melanoma J. Clin. Oncol., February 1, 1999; 17(2): 651 - 651. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Wadler and E. L. Schwartz New Advances in Interferon Therapy of Cancer Oncologist, August 1, 1997; 2(4): 254 - 267. [Abstract] [Full Text] [PDF]
|
|